Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + Anlotinib vs Chemotherapy in Advanced Biliary Cancer
NCT04809142Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart in biliary cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
biliary cancer
Beyond the preview
Go deeper on NCT04809142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809142.